Though the pandemic and political feuding have slowed legislative progress, industry insiders say momentum is building for action next year. Take a look at seven federal and one state bill on the docket that could shake things up across the industry, including the CBD Product Safety and Standardization Act, introduced this month. Learn more here.
Over 50% of alcohol retailers in a nationwide survey believe that CBD-infused beverages have the industry’s biggest growth potential. The annual “BevAlc Insights by Drizly Retail Report” is based on a sample of more than 500 retailers. Drizly is North America’s largest e-commerce alcohol marketplace. Read about it here.
Inhaled CBD shrank the size of the highly aggressive lethal brain tumor glioblastoma in an animal model, according to a study published in Cannabis and Cannabinoid Research. After only seven days of treatment, “We saw a significant reduction in the size of the tumor,” said researcher and immunologist Babak Baban, MD, PhD. Get the details.
A Leafreport study of 38 products highlights the challenge of meeting label claims of not just one, but two cannabinoids. An independent lab found CBD claims off by 10.4% to 64.7%. The study found that products from leading brands performed better than those from smaller companies. Dig into the results here.
Debate about regulating the compound dominated headlines in 2021. Respondents to a recent Cannabis Business Times/Hemp Grower survey were split as to whether delta-8 should be regulated as hemp or in the state-legal cannabis market. Get both sides here.